Citi Pharma receives CCP nod to acquire Pakheim International

Citi Pharma Limited (CPHL) has obtained approval from the Competition Commission of Pakistan for its planned purchase of all shares in Pakheim International Pharma (Private) Limited. According to Business Recorder, the company informed the Pakistan Stock Exchange in a filing on Monday. The order, issued on October 9, 2026 under Case No. 1614/Merger-CCP/2026, relies on Section 31(1)(d)(i) of the Competition Act, 2010 to allow the deal.

The CCP concluded the deal poses no competitive problems. Under the Share Purchase Agreement dated May 6, 2026, the acquisition will go ahead once legal, regulatory and other formalities are completed. Citi Pharma had first flagged the plan in May as part of its growth strategy.

At the time of the May announcement, Citi Pharma said Pakheim generates roughly Rs500 million in annual revenue, which it aims to lift to Rs5 billion within five years through wider product lines, stronger distribution and manufacturing investment. The company also described a flexible payment schedule running until December 31, 2026, to be funded from operating cash flows. It expects the deal to boost API sales and give its trading business a fresh brand identity.